Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung Cancer

Developments in the management of EGFR-mutated NSCLCПодробнее

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLCПодробнее

Osimertinib with Chemotherapy in EGFR-Mutated NSCLC | NEJMПодробнее

The FLAURA Trial: Practice-Changing Results for EGFR Mutation-Positive NSCLC (BMIC-007)Подробнее

TAGRISSO - 84% Reduction in Disease in Stage III EGFR-Mutated Lung Cancer: LAURA TrialПодробнее

Dr. Ramalingam on FLAURA Trial Results in EGFR-Mutant NSCLCПодробнее

FLAURA2: EGFRm dynamics in NSCLC treated with osimertinibПодробнее

Trials in EGFR Mutated NSCLC: Mariposa2 and Laura- 2024 Leading Developments in Lung CancerПодробнее

FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung CancerПодробнее

Trials in ALK+ NSCLC: The Crown Study- 2024 Leading Developments in Lung CancerПодробнее

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinibПодробнее

FLOWERS: osimertinib and savolitinib in MET aberrant, EGFRm NSCLCПодробнее

Treating EGFR-Mutated NSCLC - 10/15/24 - Lung Cancer Living Room™Подробнее

Understanding NSCLC Treatment When You Have an EGFR MutationПодробнее

The ADAURA Trial: Flaws and Results - Leading Developments & Current Questions in Lung CancerПодробнее

Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLCПодробнее

Treatment for Patients with EGFR+ NSCLC - Leading Developments & Current Questions in Lung CancerПодробнее

MARIPOSA: mechanisms of resistance to 1L amivantamab + lazertinib in pts with EGFR-m NSCLCПодробнее

ADAURA Trial: Tagrisso & Resectable EGFR+ - Leading Developments & Current Questions in Lung CancerПодробнее